Understanding genetics in cannabis use disorder and response to cannabinoids

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how genetic factors influence an individual's risk for cannabis use disorder (CanUD) and their response to cannabinoids. It aims to explore the relationship between genetics and the development of CanUD, as well as the effectiveness of treatments for this condition. Participants will receive either Delta-9-THC or a placebo to assess their responses. The research is particularly relevant given the increasing prevalence of cannabis use and its associated risks.

Why it matters

Who can join: the full rules

Inclusion Criteria:

-Ages 21-60 years old

Exclusion Criteria:

* Major or unstable medical conditions based on history, the Structured Clinical Interview for DSM-5, collateral information, physical and laboratory examinations, ECG, and vital signs.
* Cannabis naïve individuals
* Positive pregnancy test

Where it's running

• West Haven Veterans Affairs Medical Center
  West Haven, Connecticut, United States Recruiting

Study contacts

• Principal investigator: Deepak D'Souza, MD — Yale University
• Study coordinator: Erik Zorrilla, PhD
• Email: erik.zorrilla@yale.edu
• Phone: 203-932-5711

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Lumateperone to improve motivation in patients with schizophrenia and psychosis

  This study is testing if Lumateperone can help people with schizophrenia or schizoaffective disorders feel more motivated and less apathetic.

  Recruiting Phase 3 Louisiana State University Health Sciences Center Shreveport · Shreveport, Louisiana · NCT06482554

• Examining the effects of combined therapy for schizophrenia

  This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.

  Recruiting at 2 sites University of Toronto · Scarborough Village, Ontario and 1 other locations · NCT05731414

• Investigating cognitive function in psychosis patients and cannabis users

  This study is testing how taking a break from cannabis for 28 days affects thinking skills and brain activity in people with psychosis and those who use cannabis but don’t have mental health issues.

  Recruiting Douglas Mental Health University Institute · Montreal, Quebec · NCT05445180

• Can tACS modulate motivation and reward signals in cannabis use disorder and depression

  We’re testing whether a gentle brain stimulation method (tACS) can boost motivation and reward responses in adults with cannabis use and/or depression to see if it helps with anhedonia.

  Recruiting Florida State University · Tallahassee, Florida and 1 other locations · NCT07924852

• XEP527 in stable schizophrenia: safety and how it behaves in the body

  This small, early-stage study tests the safety and how XEP527 behaves in people with stable schizophrenia who are on a single antipsychotic.

  Recruiting Phase 1 Novartis · Bentonville, Arkansas · NCT07908680

• Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations

  This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.

  Recruiting Ciusss de L'Est de l'Île de Montréal · Montreal, Quebec · NCT07902518

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.